BioStem Technologies, Inc.
NASDAQ:BSEMBiotechnology
-$0.21 today
- Market cap
- $52.14M
- Beta
- 0.26
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.63
Volume 0.09M
Average 0.07M
BSEM Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
BioStem Technologies, Inc.NASDAQ: BSEM
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $2.36M rose 108.6% year over year, ahead of the -7.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 52.4% from the prior quarter.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +108.6% holds above the trailing-twelve-month pace of -7.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 6.67M | +36.0% |
| FY2022 | 2022-12-31 | 4.9M | +1116.6% |
| FY2021 | 2021-12-31 | 403.02K | — |
Stock-Based Compensation vs competitors
How BSEM compares with its peers on the latest reported figures
No competitor Stock-Based Compensation figures are available to compare.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.41M) | (7.11M) | (8.48M) | 31.88M | (6.58M) |
| Depreciation & Amortization | 283.79K | 243.42K | 395.32K | 293.22K | 381.02K |
| Deferred Income Tax | (689.36K) | 0 | 0 | 0 | 3.99M |
| Stock-Based Compensation | 403.02K | 4.9M | 6.67M | 0 | 0 |
| Change in Working Capital | 515.9K | 7.59K | (3.54M) | (12.01M) | (3.98M) |
| Accounts Receivables | (288.25K) | 262.93K | (11.33M) | (93.78M) | 4.43M |
| Inventory | 209.35K | (135.18K) | (263.45K) | (1.17M) | (1.05M) |
| Accounts Payables | (19.49K) | (77.14K) | 821.57K | 4.42M | (1.5M) |
| Other Working Capital | 614.3K | (43.03K) | 8.06M | 78.52M | (5.86M) |
| Other Non-Cash Items | 788.99K | 322.58K | 1.46M | 4.31M | 16.12M |
| Operating Cash Flow | (109.44K) | (1.64M) | (3.5M) | 24.48M | 9.94M |
| Capital Expenditures | (42.85K) | (469.48K) | (105.33K) | (426.57K) | (3.35M) |
| Acquisitions (Net) | 35K | 0 | (105K) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (1.25M) | 1.25M |
| Investing Cash Flow | (7.85K) | (469.48K) | (210.33K) | (1.68M) | (2.1M) |
| Debt Repayment | 232.42K | 547.71K | 797.06K | (849.4K) | (1.17M) |
| Common Stock Issued | 125K | 50K | 2.38M | 642.62K | 48.33K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (391.79K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 357.42K | 597.71K | 3.18M | (206.78K) | (1.12M) |
| Effect of Forex Changes | 0 | 1.97M | 0 | 0 | 0 |
| Net Change in Cash | 240.13K | 431.8K | (532.73K) | 22.59M | 6.72M |
| Free Cash Flow | (152.29K) | (2.11M) | (3.6M) | 24.05M | 6.59M |
BioStem Technologies, Inc.
NASDAQ:BSEM
Intrinsic Alpha fair value
Locked
Current Price
$3.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.